title: The effects of the TRPV1 receptor antagonist SB-705498 on trigeminovascular sensitisation and neurotransmission.
abstract: This report examines the effect of the transient receptor potential vanilloid 1 receptor antagonist SB-705498 on neurotransmission and inflammation-induced sensitisation in the trigeminovascular sensory system. A single-neuron electrophysiological animal model for neurovascular head pain was used to evaluate dural and facial noxious inputs and the effects of SB-705498 administered by intravenous (i.v.) injection. Electrical and mechanical stimulation of the dura mater and the facial skin activated second-order neurons in the trigeminal nucleus caudalis of cats, with A-delta latencies. Intravenous injection of SB-705498 (2 mg kg(-1)) produced a slowly developing and long-lasting suppression of responses to dural and skin stimulation. Maximum suppression occurred by 1 h and reached 41% for dura and 24% for skin. Intravenous injection of drug vehicle did not produce significant suppression of responses to stimulation of either dura or skin. Intravenous injection of SB-705498 produced a brief and small rise in blood pressure and dural blood flow, which both returned to normal before suppression of the responses to stimulation became manifest. Application of "inflammatory soup" to the dura mater produced a pronounced increase in dural blood flow and induced a slowly developing increase in the responses of neurons to both electrical and mechanical stimulations of their facial and dural receptive fields. This sensitisation reached a maximum in 60-90 min, at which time responses had risen to approximately twice that of control levels seen before the application of inflammatory soup. Intravenous injection of SB-705498 subsequent to the development of sensitisation produced a slowly developing, prolonged and statistically significant reversal of the sensitisation induced by inflammatory soup. Maximum reversal of sensitisation to electrical stimulation occurred by 150-180 min, when responses had fallen to, or below, control levels. At 70-85 min following injection of SB-705498, the responses of previously sensitised neurons to mechanical stimulation of dura mater and facial receptive field had also returned to near control levels. SB-705498 was also able to prevent the development of sensitisation; application of inflammatory soup to the dura mater induced a slowly developing increase in the responses of neurons to electrical stimulation of the skin and dura mater in cats which had received an i.v. injection of vehicle for SB-705498 but not in cats which had received the active drug. Blood levels of SB-705498 were maximal immediately following i.v. injection and declined over the following 2 h. Significant brain levels of SB-705498 were maintained for up to 9 h. These results suggest that SB-705498 may be an effective suppressant and reversal agent of the sensitisation to sensory input which follows inflammation in the trigeminovascular sensory distribution but may not be particularly useful in blocking primary pain processes such as migraine headache. SB-705498 could thus potentially prevent, modify or reverse the cutaneous trigeminal allodynia seen in certain migraine conditions, especially "transformed" migraine.
authors.affiliation: Institute of Neurological Sciences, University of New South Wales and Prince of Wales Hospital, Randwick, Sydney 2031, Australia. G.Lambert@unsw.edu.au
authors.forename: G A
authors.initials: GA
authors.lastname: Lambert
authors.forename: J B
authors.initials: JB
authors.lastname: Davis
authors.forename: J M
authors.initials: JM
authors.lastname: Appleby
authors.forename: B A
authors.initials: BA
authors.lastname: Chizh
authors.forename: K L
authors.initials: KL
authors.lastname: Hoskin
authors.forename: A S
authors.initials: AS
authors.lastname: Zagami
mesh_terms: D000700:Analgesics / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002415:Cats; D002560:Cerebrovascular Circulation / Q000187:drug effects; D004195:Disease Models, Animal; D004388:Dura Mater / Q000098:blood supply*; D004558:Electric Stimulation; D005071:Evoked Potentials; D005145:Face; D007249:Inflammation / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D018836:Inflammation Mediators / Q000378:metabolism; D007275:Injections, Intravenous; D008881:Migraine Disorders / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D009413:Nerve Fibers, Myelinated / Q000187:drug effects / Q000378:metabolism; D010146:Pain / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D010147:Pain Measurement; D017288:Pain Threshold / Q000187:drug effects; D011759:Pyrrolidines / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D011930:Reaction Time / Q000187:drug effects; D012867:Skin / Q000294:innervation*; D009435:Synaptic Transmission / Q000187:drug effects*; D050916:TRPV Cation Channels / Q000037:antagonists & inhibitors* / Q000378:metabolism; D013997:Time Factors; D014275:Trigeminal Caudal Nucleus / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D014276:Trigeminal Nerve / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D014508:Urea / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood / Q000494:pharmacology
chemical_list: D000700:Analgesics; D018836:Inflammation Mediators; D011759:Pyrrolidines; C512301:SB 705498; D050916:TRPV Cation Channels; D014508:Urea
references.citation: Nat Rev Drug Discov. 2007 May;6(5):357-72
references.pmid: 17464295
references.citation: J Physiol. 2001 Aug 1;534(Pt 3):805-12
references.pmid: 11483710
references.citation: Circ Res. 2004 Nov 12;95(10):1027-34
references.pmid: 15499026
references.citation: Headache. 2006 Nov;46 Suppl 4:S182-91
references.pmid: 17078850
references.citation: Brain Res. 1992 Dec 4;597(2):321-30
references.pmid: 1473003
references.citation: Neurosci Lett. 2002 Sep 27;330(3):223-6
references.pmid: 12270633
references.citation: Pain. 1986 Jun;25(3):395-401
references.pmid: 3748590
references.citation: N Engl J Med. 2004 Mar 11;350(11):1073-5
references.pmid: 15014178
references.citation: J Physiol. 2003 Apr 1;548(Pt 1):121-9
references.pmid: 12562891
references.citation: J Cereb Blood Flow Metab. 1996 May;16(3):507-16
references.pmid: 8621756
references.citation: Curr Pain Headache Rep. 2006 Jun;10(3):167-78
references.pmid: 18778570
references.citation: Nature. 1996 Dec 12;384(6609):560-4
references.pmid: 8955268
references.citation: Am J Physiol Regul Integr Comp Physiol. 2007 Jan;292(1):R64-76
references.pmid: 16973931
references.citation: Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3655-60
references.pmid: 10725386
references.citation: Ann Neurol. 2004 Jan;55(1):27-36
references.pmid: 14705109
references.citation: Bioorg Med Chem Lett. 2006 Jun 15;16(12):3287-91
references.pmid: 16580202
references.citation: J Neurosci. 2006 Sep 13;26(37):9385-93
references.pmid: 16971522
references.citation: Br J Pharmacol. 1999 Jun;127(3):623-30
references.pmid: 10401552
references.citation: CNS Drugs. 2004;18(6):337-42
references.pmid: 15089101
references.citation: Brain Res Brain Res Rev. 2001 Mar;35(1):20-35
references.pmid: 11245884
references.citation: Pain. 2007 May;129(1-2):195-209
references.pmid: 17317009
references.citation: Headache. 2009 Feb;49(2):253-75
references.pmid: 18793210
references.citation: Regul Pept. 1992 Jun 11;39(2-3):123-35
references.pmid: 1279751
references.citation: J Pharmacol Exp Ther. 2007 Jun;321(3):1183-92
references.pmid: 17392405
references.citation: Br J Pharmacol. 2003 Mar;138(5):977-85
references.pmid: 12642400
references.citation: Ann Neurol. 2000 May;47(5):614-24
references.pmid: 10805332
references.citation: Nature. 1987 Jan 8-14;325(7000):151-3
references.pmid: 3808072
references.citation: Br J Pharmacol. 1999 Mar;126(6):1478-86
references.pmid: 10217543
references.citation: J Comp Neurol. 1991 Jul 22;309(4):515-34
references.pmid: 1717522
references.citation: Brain Res. 2003 Feb 14;963(1-2):190-6
references.pmid: 12560124
references.citation: Eur J Pharmacol. 2006 Jul 1;540(1-3):73-81
references.pmid: 16737693
references.citation: J Neurochem. 2001 Mar;76(6):1628-35
references.pmid: 11259480
references.citation: Headache. 2007 Apr;47(4):531-9
references.pmid: 17445102
references.citation: Brain Res. 1983 May 23;268(1):162-6
references.pmid: 6190538
references.citation: Nature. 1983 Dec 15-21;306(5944):686-8
references.pmid: 6656869
references.citation: Headache. 2003 Jul-Aug;43(7):704-14
references.pmid: 12890124
references.citation: J Neurophysiol. 1998 Feb;79(2):964-82
references.pmid: 9463456
references.citation: Headache. 2004 Nov-Dec;44(10):1010-2
references.pmid: 15546264
references.citation: Headache. 2007 Apr;47 Suppl 1:S26-43
references.pmid: 17425708
references.citation: Neuropharmacology. 2004 Jul;47(1):92-105
references.pmid: 15165837
references.citation: J Neurosci Methods. 2009 Mar 15;177(2):420-6
references.pmid: 19041344
references.citation: Cephalalgia. 2008 Jun;28(6):640-52
references.pmid: 18454788
references.citation: Brain Res. 2007 Oct 10;1173:84-91
references.pmid: 17765209
references.citation: Neuroscience. 1999;90(4):1371-6
references.pmid: 10338304
references.citation: Peptides. 1992 May-Jun;13(3):527-36
references.pmid: 1381830
references.citation: J Neurosci. 2005 Jun 22;25(25):5877-83
references.pmid: 15976076
references.citation: J Neurophysiol. 2007 Jan;97(1):503-11
references.pmid: 17065246
references.citation: Eur J Neurosci. 1999 Mar;11(3):946-58
references.pmid: 10103088
references.citation: Am J Physiol. 1991 Jul;261(1 Pt 2):H96-102
references.pmid: 1858935
references.citation: Nature. 1986 May 29-Jun 4;321(6069):519-22
references.pmid: 3012362
references.citation: Brain Res. 2000 Feb 7;855(1):107-15
references.pmid: 10650136
references.citation: Brain Res. 1986 Aug 6;379(2):242-50
references.pmid: 3742223
references.citation: J Chem Neuroanat. 2007 Nov;34(3-4):95-101
references.pmid: 17587545
references.citation: J Pain. 2007 Mar;8(3):263-72
references.pmid: 17113352
references.citation: Mol Pharmacol. 2002 Oct;62(4):947-56
references.pmid: 12237342
references.citation: Acta Neurol Scand. 1994 Nov;90(5):324-30
references.pmid: 7534026
references.citation: Cephalalgia. 2002 Jul;22(6):424-31
references.pmid: 12133041
references.citation: J Neurophysiol. 1984 Jul;52(1):39-53
references.pmid: 6747677
references.citation: Ann Neurol. 2004 Sep;56(3):371-81
references.pmid: 15349864
references.citation: Headache. 2007 Jul-Aug;47(7):1008-23; discussion 24-5
references.pmid: 17635592
references.citation: Nat Rev Drug Discov. 2005 Sep;4(9):741-50
references.pmid: 16121129
references.citation: Brain Res. 1983 Aug 22;273(1):35-44
references.pmid: 6616230
references.citation: J Neurosci. 1998 Dec 15;18(24):10375-88
references.pmid: 9852575
references.citation: Headache. 2005 Jul-Aug;45(7):850-61
references.pmid: 15985101
references.citation: Br J Pharmacol. 2006 Jan;147 Suppl 1:S202-11
references.pmid: 16402106
references.citation: Neurology. 2008 Apr 15;70(16):1304-12
references.pmid: 17914062
references.citation: J Comp Neurol. 2001 Jul 23;436(2):225-35
references.pmid: 11438926
references.citation: Neurosci Lett. 1999 May 14;266(3):173-6
references.pmid: 10465701